P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
373 Indexnicotinic acetylcholine receptor, 25
nifedipine, 253 –254
nimodipine, 254
nitrates, 249 –251
organic,131t
tolerance, 39
nitric oxide (NO),130t, 132t
adult intensive care use guidelines,
131t, 132t
effects,131t
guanylyl cyclase stimulation, 30
inhaled, 13
synthesis,130t, 131t
nitric oxide synthase (NOS)
constitutive,130t, 131t
inducible,130t, 131t
nitrites, 248 –249
nitroimidazoles,328t
nitrous oxide (N 2 O),120f
concentration effect, 118 –120
diffusion hypoxia, 120
effects, 118
manufacture, 117 –118
second gas effect, 120
storage, 118
toxicity, 120 –121
nizatidine, 294
NMDA receptor,2–3, 26, 102
ketamine antagonism with glutamate,
37
L-NMMA,131t
non-compartment models, 71
volume of distribution, 72 –73
non-linear kinetics,79f
non-steroidal anti-inflammatory drugs
(NSAIDs), 135 –136, 149–152
asthma, 151
classification,152t
clinical data,157t
drug interactions, 152
gastric irritation, 151 –152
hepatotoxicity, 152
kinetics,157t
mechanisms of action, 149 –151
platelets, 151 –152
renal function, 151 –152
NOP receptor, 137 –139
noradrenaline, 203 –204
effects, 203
kinetics, 204
mechanism of action, 203
metabolism, 18
presentation, 203
release, 197 –199
uses, 203norfloxacin, 320 –321
nortriptyline, 274 –276
nucleic acids, 86
nucleosides, 86
nucleotides, 86oestrogen therapy, 358 –359
ofloxacin, 320 –321
omeprazole, 294 –295
ondansetron, 290 –291
one-compartment model, 64 –68
clearance of drug, 73
time constant, 74
volume of distribution, 72
opioids, 91 , 135–149
minimizing of administration, 282
partial agonists,139t, 149
pharmacological properties,138t
receptors, 136 , 136t, 137t, 139
structure,140f
oral administration,8–11
bioavailability,9–11
oral contraceptives, 358
failure with antibiotics, 21
organic chemistry, 85
organophosphorus compounds, 195 –196, 196f
osmotic diuretics, 309 –310
oxicam group, 95 , 158
oxidation, 17 –18
oxygen, 128 , 130t
effects,130t
manufacture, 128
measurement,130t
storage, 128
toxicity,130t
uses,130tpain, 135
modification, 135 –136
physiology, 135 –136
pancuronium, 187 –188
volume of distribution, 72
papaveretum, 142 –143
papaverine, 90 , 96, 142–143
para-aminophenols, 154 –156
paracetamol, 154 –156
kinetics, 155
overdose, 155 –156
presentation, 154 –155
structure,152f
toxicity, 155
uses, 154 –155
parasympathetic nervous system, 197
parecoxib, 161
kinetics, 161